Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | RAB9A | P51151 | 12/20 | 0.64 |
| ▸ | NPC1 | O15118 | 10/20 | 0.64 |
| ▸ | SMN1; SMN2 | Q16637 | 9/20 | 0.64 |
| ▸ | ALDH1A1 | P00352 | 7/20 | 0.64 |
| ▸ | HPGD | P15428 | 7/20 | 0.64 |
| ▸ | KDM4E | B2RXH2 | 5/20 | 0.64 |
| ▸ | MAPT | P10636 | 3/20 | 0.64 |
| ▸ | LMNA | P02545 | 2/20 | 0.64 |
| ▸ | TSHR | P16473 | 1/20 | 0.62 |
| ▸ | ATR | Q13535 | 1/20 | 0.60 |
| ▸ | MEN1 | O00255 | 1/20 | 0.59 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.59 |
| ▸ | TP53 | P04637 | 1/20 | 0.58 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.58 |
| ▸ | EGFR | P00533 | 1/20 | 0.57 |
| ▸ | NFKB1 | P19838 | 2/20 | 0.57 |
| ▸ | NFKB2 | Q00653 | 2/20 | 0.57 |
| ▸ | RELA | Q04206 | 2/20 | 0.57 |
| ▸ | HSD17B10 | Q99714 | 1/20 | 0.55 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.55 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4820143 | 0.87 | RAB9A (0.66) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL12171732 | 0.85 | NPC1 (0.66) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL8057350 | 0.85 | KDM4E (0.67) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL28800094 | 0.83 | ALDH1A1 (0.54) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL11816106 | 0.83 | RAB9A (0.72) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL12171886 | 0.82 | PPARD (0.56) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL20533001 | 0.81 | EGFR (0.52) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL6451390 | 0.81 | ALDH1A1 (0.59) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL5338382 | 0.81 | NPC1 (0.66) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD | |
| SCHEMBL9341648 | 0.81 | RAB9A (0.57) | RAB9ANPC1SMN1; SMN2ALDH1A1HPGD |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| CN-104685416-B | Photosensitive polymer combination, using its cured film preparation method, cured film, liquid crystal display device and organic EL display device | 富士胶片株式会社 | 2019-05-14 | — | — | CN | disclosed |
| CN-104685416-A | Photosensitive resin composition, method for forming cured film using same, cured film, liquid crystal display device, and organic el display device | FUJIFILM CORP | 2015-06-03 | — | — | CN | disclosed |
| CN-104059058-A | Compositions and methods for controlling nematodes | MONSANTO TECHNOLOGY LLC | 2014-09-24 | — | — | CN | disclosed |
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | ANADYS PHARMACEUTICALS, INC. (US) | 2005-04-07 | — | — | US | disclosed |
| WO-2004110351-A2 | HETEROCYCLIC COMPOUNDS FOR TREATING HEPATITIS C VIRUS | ANADYS PHARMACEUTICALS, INC. (US) | 2004-12-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050075375-A1 | Heterocyclic compounds for treating hepatitis C virus | HAVCR2, HCCS, LIPC | RAB9A 2483/4885NPC1 59/4885SMN1; SMN2 4633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.